|

A Prospective Observational Study of Foam Sclerotherapy .

RECRUITINGSponsored by Mayo Clinic
Actively Recruiting
SponsorMayo Clinic
Started2017-11-06
Est. completion2027-11
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04111692

Summary

An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).

Eligibility

Age: 18 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years
* Clinical diagnosis of ADPKD or ADPLD
* 1-3 large, non-exophytic liver or kidney cyst
* Compressive symptoms from dominant cyst

Exclusion Criteria:

* Age \<18 years
* Absence of ADPKD or ADPLD
* Largest cyst \<4cm in all 3 dimensions or largest cyst volume \<400cc
* \>3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc)
* Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS
* Lacking capacity to provide informed consent to FS of liver or kidney cysts
* Pregnancy

Conditions5

Autosomal Dominant Polycystic KidneyAutosomal Dominant Polycystic Liver DiseaseHepatic CystLiver DiseaseRenal Cyst

Locations1 site

Mayo Clinic
Rochester, Minnesota, 55905
Marie C Hogan, MD, PhD507-266-1963hogan.marie@mayo.edu

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.